EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 3.0

Update on the treatment navigation for functional cure of chronic hepatitis B: Expert consensus 2.0

Di Wu, Jia-Horng Kao, Teerha Piratvisuth, Xiaojing Wang, Patrick T F Kennedy, Motoyuki Otsuka, Sang Hoon Ahn, Yasuhito Tanaka, Guiqiang Wang, Zhenghong Yuan, Wenhui Li, Young-Suk Lim und 14 weitere

Clinical and Molecular Hepatology · 2025

DOI: 10.3350/cmh.2024.0780 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical and Molecular Hepatology, 2025. Verfasst von Di Wu und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Tongji Hospital, Tongji Medical College and State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic In…. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Antiviral Agents. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 232 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Chinese National Thirteenth-Five Years Project in Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As new evidence emerges, treatment strategies toward the functional cure of chronic hepatitis B are evolving. In 2019, a panel of national hepatologists published a Consensus Statement on the functional cure of chronic hepatitis B. Currently, an international group of hepatologists has been assembled to evaluate research since the publication of the original consensus, and to collaboratively develop the updated statements. The 2.0 Consensus was aimed to update the original consensus with the latest available studies, and provide a comprehensive overview of the current relevant scientific literatures regarding functional cure of hepatitis B, with a particular focus on issues that are not yet fully clarified. These cover the definition of functional cure of hepatitis B, its mechanisms and barriers, the effective strategies and treatment roadmap to achieve this endpoint, in particular new surrogate biomarkers used to measure efficacy or to predict response, and the appropriate approach to pursuing a functional cure in special populations, the development of emerging antivirals and immunomodulators with potential for curing hepatitis B. The statements are primarily intended to offer international guidance for clinicians in their practice to enhance the functional cure rate of chronic hepatitis B.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis B, ChronicAntiviral AgentsHumansHepatitis B virusBiomarkersImmunologic FactorsTreatment OutcomeHepatitis B Surface Antigens

Stichwörter der Autor:innen

Antiviral AgentsChronic hepatitis BConsensusHBsAgImmunologic Factors

Substanzen

Antiviral AgentsBiomarkersImmunologic FactorsHepatitis B Surface Antigens

Autor:innen und Institutionen

  • Department of Infectious Diseases, Tongji Hospital, Tongji Medical College and State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Disease, Huazhong University of Science and Technology, Wuhan…
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan.
  • NKC Institute of Gastroenterology and Hepatology, Songklanagarind Hospital, Prince of Songkla University, Hat Yai, Thailand.
  • Barts Liver Centre, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
  • Department of Gastroenterology and Hepatology, Academic Fields of Medicine, Dentistry, and Pharmaceutical Science, Okayama University, Okayama, Japan.
  • Department of Internal Medicine, Yonsei University College of Medicine, Yonsei Liver Center, Severance Hospital, Seoul, Korea.

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • Chinese National Thirteenth-Five Years Project in Science and Technology
  • Roche Diagnostics
  • Janssen
  • VIR
  • GSK
  • Sysmex

Zitieren

APA

Wu, D., Kao, J. H., Piratvisuth, T., Wang, X., Kennedy, P. T. F., Otsuka, M., Ahn, S. H., Tanaka, Y., Wang, G., Yuan, Z., Li, W., Lim, Y. S., Niu, J., Lu, F., Zhang, W., Gao, Z., Kaewdech, A., Han, M., Yan, W., …, & Ning, Q. (2025). Update on the treatment navigation for functional cure of chronic hepatitis B: Expert consensus 2.0. Clinical and Molecular Hepatology. https://doi.org/10.3350/cmh.2024.0780

Vancouver

Wu D, Kao JH, Piratvisuth T, Wang X, Kennedy PTF, Otsuka M, et al. Update on the treatment navigation for functional cure of chronic hepatitis B: Expert consensus 2.0. Clinical and Molecular Hepatology. 2025. doi:10.3350/cmh.2024.0780

BibTeX
@article{Wu2025,
  author = {Wu, Di and Kao, Jia-Horng and Piratvisuth, Teerha and Wang, Xiaojing and Kennedy, Patrick T F and Otsuka, Motoyuki and Ahn, Sang Hoon and Tanaka, Yasuhito and Wang, Guiqiang and Yuan, Zhenghong and Li, Wenhui and Lim, Young-Suk and Niu, Junqi and Lu, Fengmin and Zhang, Wenhong and Gao, Zhiliang and Kaewdech, Apichat and Han, Meifang and Yan, Weiming and Ren, Hong and Hu, Peng and Shu, Sainan and Kwo, Paul Yien and Wang, Fu-Sheng and Yuen, Man-Fung and Ning, Qin},
  title = {Update on the treatment navigation for functional cure of chronic hepatitis B: Expert consensus 2.0},
  journal = {Clinical and Molecular Hepatology},
  year = {2025},
  doi = {10.3350/cmh.2024.0780}
}
Kostenlos starten →